In patients with symptomatic nonerosive reflux disease, intermittent on-demand therapy with the PPI rabeprazole provided good symptom control with tablets taken on average approximately 1 day out of 4. Go Back
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.